Printer Friendly

SALES OF UNITED-GUARDIAN DRUG PRODUCT GROWING 15 - 20 PERCENT ANNUALLY

 HAUPPAUGE, N.Y., Feb. 24 /PRNewswire/ -- United-Guardian, Inc. (AMEX: UG), today released the following:
 With the population continuing to grow older, more and more of the elderly are confined to homes for the aged, nursing homes and to home care. Many of these have bladder problems, incontinence, persistent urinary infections, and must wear catheters to control their conditions.
 This increase in the use of catheters has resulted in a continuous rise in the demand for Renacidin Irrigation, manufactured by United- Guardian, Inc., which keeps these catheters from becoming plugged up with calcium (which it will normally do in about two weeks). The use of Renacidin Irrigation, even once a day, results in catheters that remain open for months, thereby decreasing expensive health care, and the necessity for emergency catheter changes, often during the middle of the night.
 Despite holding the price constant since its 1991 introduction, United-Guardian is showing an increase in Renacidin Irrigation sales of 15-20 percent annually. According to Dr. Alfred R. Globus, chairman and CEO of the company, "Based on recent increased activities in the field, we expect to see a further increase in sales in 1993. And since Renacidin Irrigation is an Orphan Drug and covered by a recent U.S. patent, it is not in danger of being supplanted by generic products."
 United-Guardian is a manufacturer of pharmaceuticals, medical devices, health-care products and specialty chemicals.
 -0- 2/24/93
 /CONTACT: United-Guardian public relations, 516-273-0900/
 (UG)


CO: United-Guardian, Inc. ST: New York IN: MTC SU:

GK-SM -- NY007 -- 9773 02/24/93 09:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 24, 1993
Words:258
Previous Article:BANK OF AMERICA'S FIRST FUNDS WILL BECOME PACIFIC HORIZON FUNDS; SEI HIGH SIERRA GOVERNMENT FUND ASSETS ALSO MOVED TO PACIFIC HORIZON
Next Article:MTEL EARNS 4 CENTS PER SHARE IN FOURTH QUARTER
Topics:


Related Articles
UNITED-GUARDIAN REPORTS FISCAL YEAR 1992 EARNINGS
BIOPOOL FILES FOR FDA 510(k) PRE-MARKET NOTIFICATION APPROVAL FOR NEW PRODUCT LINE
U.S. SURGICAL CORPORATION ENTERS INFUSION PORT MARKET WITH PURCHASE OF DEVICE LABS, INC. CHEMOSITE PRODUCT LINES
INVITRO INTERNATIONAL SIGNS AGREEMENT TO EXCLUSIVELY LICENSE DNA IDENTIFICATION PRODUCTS
Overseas Markets Key to U.S. Medical Device Industry Future Report Finds; Despite Challenges, Industry Experiences Robust Growth
Overseas Markets Key to U.S. Medical Device Industry Future Report Finds; Despite Challenges, Industry Experiences Robust Growth
GUIDANT REPORTS ALL-TIME RECORD SALES AND EARNINGS.
Guardian Reports Significant Increase In Dental Sales In 2004; Company Links Success to Product Portfolio and Extensive Provider Network.
Baxter Reports First Quarter Sales Growth of 11 Percent, and EPS of $0.31; Additional Restructuring Measures to Improve Profitability Will Begin in...
Hospira Launches Biologics 'Clock' and Web Resource to Raise Awareness of Potential Biogenerics' Impact.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters